Volume 29, Issue 181 (2-2020)                   J Mazandaran Univ Med Sci 2020, 29(181): 120-124 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mozafari O, Behnampour N, Pahlevanzadeh B, Saberi S, Mozafari I, Akbari J et al . Effectiveness of Sambucus ebulus Leaf Extract in Treatment of Cutaneous Leishmaniasis: A Double Blind Clinical Trial. J Mazandaran Univ Med Sci 2020; 29 (181) :120-124
URL: http://jmums.mazums.ac.ir/article-1-13805-en.html
Abstract:   (4359 Views)
Background and purpose: Cutaneous leishmaniasis is a skin disease manifested as chronic ulcerative skin lesions. Current standard therapies for this disease are associated with some problems such as high cost, numerous side effects, need for injections, and drug resistance. Sambucus ebulus is used in treatment of skin inflammation. This study aimed at investigating the effects of S. ebulus leaf extract on cutaneous leishmanisis.
Materials and methods: This clinical trial was performed in 110 patients who were divided into intervention (n=55) and control groups (n=55). All patients received the standard treatment for leishmanisis. In addition, the intervention group received topical treatment of S. ebulus leaf extract 5%, while the control group received placebo. The therapy was continued until complete epithelialization of the lesions. Before the intervention and at the end of each week (until complete epithelialization of the lesions), healing progress and clinical characteristics of the lesions, including the size, induration, and degree of epithelialization were recorded.
Results: The intervention accelerated the decrease in mean diameter of lesions (P<0.05) but had no significant effect on the mean duration of therapy (P=0.31), treatment outcome (P=0.87), degree of recovery (P= 0.95).
Conclusion: The use of S. ebulus leaf extract ointment (5%) along with the standard therapy showed no effect on the treatment outcome of lesions caused by cutaneous leishmaniasis.
 
(Clinical Trials Registry Number: IRCT20151012024490N2)
 
Full-Text [PDF 185 kb]   (934 Downloads)    
Type of Study: Brief Report | Subject: Clinical pharmacy

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Mazandaran University of Medical Sciences

Designed & Developed by : Yektaweb